

# **Jiaxin (Jason) Niu, MD, PhD**

## **Thoracic, Head/Neck Medical Oncology**

### **CONTACT INFORMATION**

**Clinic Address:** 2946 E Banner Gateway Dr., Gilbert, AZ 85234

**Office Address:** 2940 E Banner Gateway Drive, Suite 450, Gilbert, AZ, 85234

**Phone:** (480) 466-8114

**Email:** Jiaxin.niu@bannerhealth.com

### **EDUCATION & TRAINING**

09/88-07/95 MD, China Medical University (CMU), Shenyang, China

07/95-07/98 Resident, Dept. of General Surgery, CMU

08/98-12/02 PhD, Dept. of Pharmacology, University of Illinois-Chicago (UIC)

01/03-06/04 Postdoc Fellow, Dept. of Pharmacology, UIC

07/04-06/07 Resident, Dept of Medicine, Cook County Hospital, Chicago, IL

07/07-06/10 Fellow, Dept. Hematology/Oncology, Baylor College of Medicine, Houston, TX 77030

### **CREDENTIALS**

#### **Licensures**

Full License in Arizona: 45104 (active)

Permanent License in IL: 036-117335 (inactive)

Full license in Texas: N4623 (inactive)

**Certificates** (ABIM ID 285546)

**ECFMG (06345037)** Certified 10/06/2003

**Hematology:** Certified on 11/09/2010, Exp: 12/31/2020

**Medical Oncology:** Certified on 11/10/2010, Exp: 12/31/2020

**Internal Medicine:** Certified on 8/20/2007, re-certified, Exp: 12/31/2027

#### **Procedures**

Certified in all internal medicine procedures

Bone marrow aspirate and biopsy

Intrathecal chemotherapy

### **PRACTICE**

7/2010-6/2011 Hematology/Oncology, South Texas of Comprehensive Cancer, Corpus Christi, TX

7/2011-12/2015 Medical oncology, Western Regional Medical Center (WRMC), CTCA, Goodyear, AZ

1/2016 – Present      Thoracic/Head & Neck Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ

## **LEADERSHIP**

7/2011 – 12/2015      Lead, Breast Cancer/Head & Neck Medical Oncology, Cancer Treatment Center of America, Goodyear, AZ

1/2016 – Present      Lead, Thoracic/Head & Neck Medical oncology, Banner MD Anderson Cancer Center, Gilbert, AZ

1/2018 – Present      Vice Chair, Clinical Research Committee

7/2019 – Present      Director, Lung Cancer Program, Banner MD Anderson Cancer Center, Gilbert, AZ

## **HONORS & AWARDS**

**Best Paper Award**, Division for Molecular Pharmacology of ASPET, Orlando, 2001

**Graduate Student Travel Award**, ASPET, Orlando, 2001

**Predoctoral Student Travel Award**, American Society for Cell Biology, San Francisco, 2002

**Young Scientist Travel Award**, ASPET, San Diego, 2003

**AHA Predoctoral Fellowship**, American Heart Association 2001-2003, \$47,000

**BMDACC Foundation Research Project Award**, REGARD Study, 2016-2017, \$60,000

## **PROFESSIONAL MEMBERSHIP**

American Society of Clinical Oncology (ASCO): 84168

American Association for Cancer Research (AACR): 384609

International Association for the Study of Lung Cancer (IASLC): 426169

## **EXPERIENCE:**

### **Teaching**

1998-2003      PhD student molecular biology, cell biology at UIC

2004-2007      Residents and med students from Rush University at cook county hospital, Chicago

2007-2010      Residents and med students at Baylor College of Medicine, Houston

2011-Present      Residents, Medical students, PA students, PAs, nursing staffs

### **Lectures**

3/2016      3 Lectures to residents at Banner University Hospital on Lung cancer, Head and Neck Cancer, Breast cancer

3/2017            Lectures to residents at Banner University Hospital on Lung cancer

3/2019            Lectures to residents at Banner University Hospital on Lung cancer

### **Research (Basic and Clinical)**

8/1998-6/2004      Department of Pharmacology, UIC, Chicago  
Basic research in signal transduction using techniques in molecular biology, pharmacology and cell biology

7/2007-6/2011      Participation in clinical research as a fellow/staff physician.

7/2011-Present      PI, Co-PI of clinical trials (completed over 20 early phase studies)

### **Currently Open:**

1.      A Multicenter, Open Label, Phase 1b Clinical Study of CMP-001 in Combination with Pembrolizumab in Subjects with Advanced Melanoma  
Sponsor of the study: **Checkmate Pharmaceuticals**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
2.      A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors  
Sponsor of the study: **Merck**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
3.      An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors  
Sponsor of the study: **Replimune**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
4.      A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Non-small Cell Lung Cancer (NSCLC), LUD 2014-VAC  
Sponsor of the study: **Ludwig Cancer Research**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
5.      A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer  
Sponsor of the study: **Takeda**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**

6. A Phase 1 Study of RGX-104 With or Without Nivolumab in Patients with Advanced Solid Malignancies and Lymphoma  
Sponsor of the study: **Rgenix**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
7. A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms  
Sponsor of the study: **MacroGenics**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **Sub-PI**
8. KEYNOTE-671: A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer  
Sponsor of the study: **Merck**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **Sub-PI**
9. A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors  
Sponsor of the study: **Exelixis**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
10. A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with anti-PD1 Antibody  
Sponsor of the study: **Nanobiotix**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
11. A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo After Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma  
Sponsor of the study: **Regeneron Pharmaceuticals**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
12. An Open-Label, Multicenter, Dose-Escalation, Phase Ia/Ib Study to Evaluate Safety, Pharmacokinetics, and therapeutic Activity of RO6874281, An Immunocytokine consisting of Interleukin a Variant (IL-2v) Targeting Fibroblast

Activation Protein  $\alpha$ , as a Single Agent (Part A) or in Combination with Trastuzumab or Cetuximab (Part B or C)

Sponsor of the study: **Roche**

Study Site: BMDACC, Gilbert, AZ

Role of the study: **PI**

13. A Phase I/II study of HB-201 as monotherapy or in combination with nivolumab in patients with human Papillomavirus 16 positive (HPV 16+) confirmed cancers

Sponsor of the study: **Hookipa Biotech**

Study Site: BMDACC, Gilbert, AZ

Role of the study: **PI**

14. A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A\*02:01+ Subjects with Relapsed/Refractory HPV16+ Cancers

Sponsor of the study: **Kite Pharma**

Study Site: BMDACC, Gilbert, AZ

Role of the study: **PI**

#### **Currently Pending:**

15. A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)

Sponsor of the study: **Boston Pharmaceuticals**

Study Site: BMDACC, Gilbert, AZ

Role of the study: **PI**

16. A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1\*04:01 Positive Subjects with Advanced Cancers

Sponsor of the study: **Kite Pharma**

Study Site: BMDACC, Gilbert, AZ

Role of the study: **PI**

17. REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Sponsor of the study: **EpicenRx**

Study Site: BMDACC, Gilbert, AZ

Role of the study: **Sub-PI**

18. A Phase 1b/2 Study of Duvelisib in Combination with Pembrolizumab in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Sponsor of the study: **Verastem**

Study Site: BMDACC, Gilbert, AZ

Role of the study: **PI**

19. Master: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)  
Sponsor of the study: **Merck**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
20. RECHECK: A Phase 2, Open-label Study of **Re**-challenge Using RRX-001 in combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) or Squamous Cell Carcinoma of Head and Neck (SCCHN) after Progression of Disease (PD) on a **Check**point Inhibitor  
Sponsor of the study: **BMDACC and EpicenRx**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**

#### **Completed or Closed:**

1. Metronomic Capecitabine with Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment  
Sponsor of the study: **CTCA**  
Study Site: Western regional medical center, Goodyear, AZ  
Role of the study: **PI**
2. Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/refractory, Paclitaxel Pretreated Recurrent Ovarian and Peritoneal Carcinoma  
Sponsor of the study: **CTCA**  
Study Site: Western regional medical center, Goodyear, AZ  
Role of the study: **PI**
3. Phase Ib/II study of Hydroxychloroquine in Metastatic Estrogen Receptor Positive Breast Cancer Progressing on Hormonal therapy (Anti-Autophagy for Breast Cancer, ABC 01 study)  
Sponsor of the study: **CTCA**  
Study Site: Western regional medical center, Goodyear, AZ  
Role of the study: **PI**
4. A Pilot Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients with Newly Diagnosed Breast Cancer (STEFNE Study)  
Sponsor of the study: **CTCA**  
Study Site: Western regional medical center, Goodyear, AZ  
Role of the study: **PI**
5. Neoadjuvant Hormonal Therapy Combined with Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients with HER2-positive and ER-Positive Breast Cancer (Neo-HTTP Study)  
Sponsor of the study: **CTCA**

- Study Site: Western regional medical center, Goodyear, AZ  
 Role of the study: **PI**
6. A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 Administered to Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer  
 Sponsor of the study: **Biomarin**  
 Study Site: Western regional medical center, Goodyear, AZ  
 Role of the study: **PI**
  7. A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications.  
 Sponsor of the study: **EMD Serono**  
 Study Site: Western regional medical center, Goodyear, AZ  
 Role of the study: **Sub-PI**
  8. My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents  
 Sponsor of the study: **Genentech, Inc**  
 Study Site: Western regional medical center, Goodyear, AZ  
 Role of the study: **Sub-PI**
  9. A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Chemotherapy in Patients with Advanced Cancer (**PembroMab**)  
 Sponsor of the study: **CTCA**  
 Study Site: Western regional medical center, Goodyear, AZ  
 Role of the study: **Sub-PI**
  10. Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (Faslodex®) With or Without PD-0332991 (Palbociclib) ± Goserelin in Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy  
 Sponsor of the study: **Pfizer**  
 Study Site: Western regional medical center, Goodyear, AZ  
 Role of the study: **PI (Closed with results presented at 2015 ASCO)**
  11. A Phase I/II Trial of Temeosolimimus Plus Neratinib for Patients with Metastatic HER2-Amplified or Triple-Negative Breast Cancer  
 Sponsor of the study: **Puma Biotechnology, Inc.**  
 Study Site: Western regional medical center, Goodyear, AZ  
 Role of the study: **PI (Closed with results presented at 2014 SABCS)**
  12. Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer (Keynote 040)  
 Sponsor of the study: **Merck**  
 Study Site: Banner MD Anderson Cancer Center (BMDACC), Gilbert, AZ  
 Role of the study: **PI (Closed with results presented at 2017 ESMO)**

13. An Open-Label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine for Third-line and Later Treatment of Subjects with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)  
Sponsor of the study: **Abbvie**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
14. A Phase III, Open-label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel or MPDL3280A in Combination With Carboplatin + NAB-Paclitaxel versus Carboplatin + NAB-Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-small Cell Lung Cancer (GO29537)  
Sponsor of the study: **Roche**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
15. An Open-Label Phase 1/2 Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors (Basket Trial)  
Sponsor of the study: **Abbvie**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
16. A Phase I Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors  
Sponsor of the study: **Merck**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
17. A First-in-human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1 (PD-1), as Single Therapy and in Combination with Other Anti-cancer Therapies, in Patients with Advanced Malignancies (R2810-ONC-1423)  
Sponsor of the study: **Regeneron**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**
18. A Multicenter, Two-Part, Phase 1/2 Clinical Study of CMP-001 in Combination with Atezolizumab With or Without Radiation Therapy in Subjects with Advanced Non-Small Cell Lung Cancer  
Sponsor of the study: **Checkmate Pharmaceuticals**  
Study Site: BMDACC, Gilbert, AZ  
Role of the study: **PI**

## **PROFESSIONAL ACTIVITY**



**A. Oral Presentations/Invited Lectures:**

1. Protein Kinase A-anchoring Protein 110, AKAP110: A Novel Effector Molecule of G13 Protein  
**ASPET, Orlando, 2001**
2. A Novel Guanine Nucleotide Exchange Factor: KIAA 0521  
**Combined Meeting of CSCR and SGIM, Chicago, 2002**
3. Haemophilus Influenzae serotype F (HIF): A rare cause of septic arthritis and bacterial meningitis  
**SGIM, Chicago, 2005**
4. A Comprehensive Board Review in Hematology and Medical Oncology, MD Anderson Cancer Center/Baylor College of Medicine  
**Guest speaker, Houston, 9/2011**
5. Endocrine Therapy for ER+ Advanced Breast Cancer: Old Challenge, New Frontiers  
**Speaker, WRMC, Phoenix, 6/2014**
6. Weight of Evidence: Obesity and Breast Cancer  
**Speaker, WRMC, Phoenix, 10/2014**
7. Obesity and Breast Cancer: A Medical Oncologist's Perspective  
**Speaker, ONS congress, Orlando, 4/2015**
8. Challenges of Implementing Precision Oncology in Community Practice: A Focus on NSCLC  
**Speaker, Tucson Symposium, Tucson, 3/2017**
9. Burning down the House: An Overview of Immunotherapy Toxicities  
**Speaker, BMDACC, Gilbert, 4/2017**
10. Medical Oncology Overview for Head & Neck Cancer  
**Speaker, Second Annual Rehabilitation Conference, Phoenix, 9/2017**
11. Recent Advances and Prospect of Metastatic Non-small Cell Lung Cancer  
**Speaker, Phoenix ONS Annual Symposium, 9/2017**
12. BMDACC Research Symposium, Innovation in Oncology Session  
**Co-Chair, Phoenix, 4/2018**
13. Intratumoral Toll-like 9 (TLR9) agonist, CMP-0001, in combination with Pembrolizumab can reverse resistance to PD-1 inhibition in a phase 1b trial in subjects with advanced melanoma  
**Co-Author, Plenary Session, AACR, Chicago, 4/2018**
14. Phase 1 dose-finding study of the anti-TIGIT antibody MK-7684 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors  
**Co-Author, SITC, Washington, D.C., 11/2018**
15. Immuno-Oncology Beyond the Basics  
**Grand Round Speaker, BMDACC, Gilbert, 6/2019**
16. Immunotherapy in Head & Neck Cancer: where are we now and where we are going?  
**Speaker, ATSU, Gilbert, 8/2019**
17. Response Evaluation Criteria In Solid Tumor (RECIST 1.1)  
**Speaker, BMDACC, 10/2019**
18. Immune Response Evaluation Criteria In Solid Tumor (iRECIST)  
**Speaker, BMDACC, 10/2019**
19. Induction of durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a Toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab

**B. Poster Presentations (First and Co-author):**

1. Synergistic cytotoxicity of digoxin and 5-fluorouracil in doxorubicin-resistant breast cancer cell lines  
**SABCS, San Antonio, 12/2013**
2. A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2-targeted therapy  
**SABCS, San Antonio, 12/2014**
3. Effective alleviation of Pegfilgrastim-induced pain with high-dose loratadine in cancer patients  
**ONS, Orlando, 4/2015**
4. Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory, paclitaxel pretreated recurrent ovarian and peritoneal carcinoma  
**ASCO, Chicago, 6/2015**
5. Prevalence and clinical significance of ESR 1 mutations in heavily pre-treated metastatic breast cancer patients  
**ESMO, Vienna, 9/2015**
6. Phase Ib/II study of pembrolizumab plus chemotherapy: Initial results of metastatic cancer patients  
**International Conference on Molecular Targets & Cancer Therapeutics, 11/2015**
7. A phase II study using metronomic capecitabine with digoxin in metastatic breast cancer patients progressing after anthracycline and taxane treatment  
**SABCS, San Antonio, 12/2015**
8. Self-reported symptoms and interference issues in breast cancer patients  
**SABCS, San Antonio, 12/2015**
9. Clinicopathologic characterization and comprehensive genomic profiling (CGP) of advanced breast cancer patients with fibroblast growth factor receptor (FGFR) alterations  
**SABCS, San Antonio, 12/2015**
10. Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors  
**ESMO, Madrid, 9/2017**
11. IHC and a new blood-based expression assay for the detection of PD-L1 in patients diagnosed with NSCLC  
**Molecular Targets and Cancer Therapeutics, Philadelphia, 10/2017**
12. Phase 1 study of cemiplimab, a fully human anti-PD-1 monoclonal antibody, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data  
**ASCO, Chicago, 6/2018**
13. Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): updated interim results from a phase 1 study  
**ASCO, Chicago, 6/2019**

**C. Peer-reviewed Publications (exclusive of abstracts):**

1. Dulin NO, Pratt P, Tiruppathi C, **Niu J**, Voyno-Yasenetskaya TA, Dunn MJ. Regulator of G Protein Signaling RGS3T is localized to the nucleus and induces apoptosis *J Biol Chem.* 2000; 275(28): 21317-23.
2. Dulin NO, **Niu J**, Browning DD, Ye RD, and Voyno-Yasenetskaya TA. Cyclic AMP-independent activation of protein kinase A by vasoactive peptides *J Biol Chem.* 2001; 276(24): 20827-30.
3. **Niu J**, Vaiscunaite R, Suzuki N, Kozasa T, Carr, D, Dulin NO, Voyno-Yasenetskaya TA. Protein kinase A-anchoring protein 110, AKAP110: A novel effector molecule of G13 protein. *Curr Biol* 2001; 11(21): 1686-90.
4. **Niu J**, Druey K, Scheschonka A, Davis A, Reed E, Kolenko V, Voyno-Yasenetskaya T, Kehrl J, Dulin NO. RGS3 interacts with 14-3-3 via the N-terminal region distinct from RGS domain. *Biochem J.* 2002; 365(Pt 3): 677-684.
5. Davis A., Hogarth K., Fernandes D., **Niu J**, and Dulin NO. Functional significance of protein kinase A activation by endothelin-1 and ATP: negative regulation of SRF-dependent gene expression by PKA. *Cell Signal.* 2003; 15(6): 597-604.
6. Adarichev V, Vaiscunaite R, **Niu J**, Voyno-Yasenetskaya TA. G  $\alpha$ 13-mediated transformation and apoptosis is permissively dependent on basal ERK. *Am J Physiol Cell Physiol* 2003; 285(4): C922-C934.
7. **Niu J**, Profirovic J, Pan H, Vaiskunaite R, Voyno-Yasenetskaya T. G Protein beta gamma subunits stimulate p114RhoGEF, a guanine nucleotide exchange factor for RhoA and Rac1: regulation of cell shape and reactive oxygen species production. *Circ Res.* 2003; 93(9): 848-56.
8. Gorovoy M, **Niu J**, Bernard O, Profirovic J, Minshall R, Neamu R, Voyno-Yasenetskaya T. LIM kinase 1 coordinates microtubule stability and actin polymerization in human endothelial cells. *J Biol Chem* 2005; 280(28): 26533-42.
9. Profirovic J, Gorovoy M, **Niu J**, Voyno-Yasenetskaya T. A novel mechanism of G-protein-dependent phosphorylation of vasodilator-stimulated phosphoprotein. *J Biol Chem.* 2005; 280(38): 32866-76.
10. Gorovoy M, Neamu R, **Niu J**, Voyno-Yasenetskaya T. RhoGDI-1 Modulation of the Activity of Monomeric RhoGTPase RhoA Regulates Endothelial Barrier Function in Mouse Lungs. *Circ Res.* 2007; 101(1): 50-8.
11. Han J, Liu G, Profirovic J, **Niu J**, Voyno-Yasenetskaya T. Zyxin is involved in thrombin signaling via interaction with PAR-1 receptor. *FASEB J.* 2009; 23(12): 4193-206.
12. Litvak DA, Malad S, Wascher RA, Markman M, **Niu J**. Laparoscopic splenectomy in colorectal cancer patients with chemotherapy-associated thrombocytopenia due to hypersplenism. *Case Rep Oncol.* 2012; 5(3): 601-7.
13. **Niu J**, Mims MP. Oxaliplatin-induced thrombotic thrombocytopenic purpura (TTP): case report and literature review. *J Clin Oncol.* 2012 Nov; 30(31): e312-4.
14. **Niu J**, Weber J, Gelbspan D. Change of HER-2 status in metastatic esophageal adenocarcinoma: heterogeneity of the disease? Case report and review of literature. *J Gastrointest Oncol.* 2012; 3(4): 358-61.
15. **Niu J**, Gelbspan D, Chong L, Birdsall S, Weitz D, et al. Lung adenocarcinoma presenting with WDHA syndrome and Marie-Bamberger syndrome. A case report. *J Clin Exp Oncol.* 2013; 2:3.

16. Baker M, Markman M, **Niu J**. Pegylated liposomal doxorubicin-induced acute transient encephalopathy in a patient with breast cancer: A case report. *Case Rep Oncol*. 2014 Mar 21;7(1):228-32.
17. Baker M, Markman M, **Niu J**. Cyclophosphamide-induced severe acute hyponatremic encephalopathy in patients with breast cancer: Report of two cases. *Case Rep Oncol*. 2014 Jul 31;7(2):550-4.
18. **Niu J**, Gelbspan D, Weitz D, Markman M, Quan W. HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: A case report. *J Gastrointest Oncol*. 2014;5(6): E103-E108
19. Turner JF, **Niu J**, Cantu C. Calcified pulmonary nodules in a patient with benign giant cell Tumor of the bone. *Ann Occup Pulm Med*. 2015; 1 (1): 13-16.
20. **Niu J**, Goldin T, Markman M, Kundranda M. Metastatic breast cancer with extensive osseous metastasis presenting with symptomatic immune thrombocytopenic purpura and anemia: A case report and literature review. *Case Rep Oncol*. 2015; 8:256–263
21. **Niu J**, Kramer K, Andres G, et al. Prevalence and clinical significance of ESR 1 mutations in heavily pre-treated metastatic breast cancer patients. *Onco targets Thera*. 2015 8:1-6
22. **Niu J**, Kundranda M, Weiss GJ, Farley J. Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory recurrent ovarian cancer. *European Journal of Gynaecologic Oncology*, 2017, 38(1):40-44
23. Weiss GJ, Waypa J, Blaydorn L, Coats Jessica, McGahey K, Sangal A, **Niu J**, Lynch CA, Farley JH, Khemka V. A Phase Ib Study of Pembrolizumab Plus Chemotherapy in Patients with Advanced Cancer (PembroPlus). *British Journal of Cancer*, 2017,117(1):33-40
24. Niu H., Zhou J., Maan H, Markman M, **Niu J**. Osimertinib for leptomeningeal disease in a patient with NSCLC harboring EGFR T790M mutation. *Case Rep Oncol* 2017,1017;10:840-845
25. Niu H., Zhou J., Phillip Koo, **Niu J**. Emergence of EGFR R451C mutation in extracellular domain during gefitinib therapy in a patient with lung adenocarcinoma harboring EGFR 19 Deletion confers resistance to gefitinib but respond to afatinib: First Case Report (*In preparation, to be submitted to JCO Precision Oncology*)
26. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsí J, Johnson ML, Moreno V, **Niu J**, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma. *N Engl J Med*. 2018 Jul 26;379(4):341-351

#### **D. Editorials & Reviews**

1. **Niu J**, Weiss G. Neoadjuvant chemotherapy in breast Cancer: A role for short-term fasting? *Breast Cancer Management* 2013; 2(6): 443-446
2. **Niu J**, Chong L, Wascher RA. What is the role of axillary lymph node dissection (if any) in breast cancer treatment? *Breast Cancer Management* 2014; 3(1): 37-42

3. **Niu J**, Sangal A, Quan W, Jr. An evolving paradigm: Addition of platinum to neoadjuvant chemotherapy in triple-negative breast cancer. *Austin Journal of Medical Oncology* 2014; 1(1): 3-5
4. Kundranda M, **Niu J**. nab-Paclitaxel in solid tumors: Clinical development and future directions. *Drug Design, Development and Therapy* 2015;9: 3767-3777
5. Pritchett MA, **Niu J**, Jackson L, Mellert H, Pestano G. Overcoming Immune Blockade in Non-Small Cell Lung Cancer: Progress and Challenges Toward a Blood-Based Assay for PD-L1. *Clinical Lab Products* 2018
6. **Niu J**, Zhou J, Lindebak S, Mahmoud F. Emerging role of immunotherapy in patients with non-small cell lung cancer with brain metastasis. *Neuroimmunology and Neuro-inflammation* 2018; 5: 32
7. Kakadia S, Yarlagadda N, Awad R, Kundranda M, **Niu J**, Naraev B, Dragovich T, Gibel M, Mahmoud F. Update on the Target Therapy in Melanoma. [Onco Targets Ther.](#) 2018;11: 7095-7107.